Kiniksa Pharmaceuticals International, plc
KNSA$3.17B
Mid CapNASDAQBiotechnology🇺🇸North America315 employees
Drugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
KNSA News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
KPL-387
Pericarditis
mavrilimumab
COVID
Rilonacept
Recurrent Pericarditis
prednisone
Giant Cell Arteritis
KPL-404
Arthritis, Rheumatoid
KPL-914
Recurrent Pericarditis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
KPL-387 | Phase 3 | Pericarditis | - | - |
mavrilimumab | Phase 3 | COVID | - | - |
Rilonacept | Phase 3 | Recurrent Pericarditis | - | - |
prednisone | Phase 2 | Giant Cell Arteritis | - | - |
KPL-404 | Phase 2 | Arthritis, Rheumatoid | - | - |
KPL-914 | Phase 2 | Recurrent Pericarditis | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply